They are going to need all those avenues of raising capital as the have quite a long glide path to potential approval. Meeting with the FDA in Q3 to just discuss what a phase 3 trial might look like. And at this point, they really don't know it they will have the efficacy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.